Skip to main content
Clinical Trials/IRCT20130313012810N18
IRCT20130313012810N18
Completed
未知

Bioequivalence study of Famotidine 40 mg coated tablets of Medava Pharmaceutical Company with Famotidine 40 mg coated tablets of Telomed Pharmaceutical Company of England

Modava Pharmaceutical Company0 sites24 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Modava Pharmaceutical Company
Enrollment
24
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Modava Pharmaceutical Company

Eligibility Criteria

Inclusion Criteria

  • The weight range of participating candidates should be between 60\-100 kg
  • Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (?\-GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose
  • Volunteers who have agreed to an informed consent form
  • All candidates should not consume caffeine\-containing drinks and chocolate during two days before the prescription, and this restriction must be followed until the last blood draw

Exclusion Criteria

  • History of allergic or adverse reaction to Azithromycin or any similar product
  • Volunteers with blood pressure less than 60/90 mm Hg or higher than 90/140 mm Hg
  • Individuals who donated whole blood or blood components within 2 months within 2 weeks prior to the first dose of the study product(s)

Outcomes

Primary Outcomes

Not specified

Similar Trials